Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM
NEJM on Twitter: "EMPEROR-Preserved: Patients w HF and preserved EF who received empagliflozin had lower risk of CV death, HF hospitalization. #ESCCongress https://t.co/uCzuuYR9jo https://t.co/cotqTxrBxN" / Twitter
Diagram of the stepwise evaluation of endpoints in the EMPEROR-Reduced... | Download Scientific Diagram
EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF | tctmd.com
EMPEROR-Preserved: A promise fulfilled - ScienceDirect
Cardiac Trials on Twitter: "SGLT2 inhibition for HFpEF?👇The first positive study with a hint of mortality reduction in HFpEF. Prior studies have largely been negative, with the notable exception of TOPCAT, wherein
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM
NEJM) Empagliflozina en pacientes con ICC y FE conservada. Estudio EMPEROR- Preserved – El rincón de Sísifo
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | NEJM
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM
EMPEROR-Preserved
Empagliflozin and Major Renal Outcomes in Heart Failure | NEJM
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM
Empagliflozin reduces hospitalization and mortality in HF with preserved EF, NEJM.
NEJM) Empagliflozina en pacientes con ICC y FE conservada. Estudio EMPEROR- Preserved – El rincón de Sísifo
NEJM on Twitter: "Ejection fraction influences effects of empagliflozin on renal outcomes, finds planned pooled analysis of two EMPEROR trials #ESCCongress https://t.co/3QrxFMKS9B https://t.co/mrEckfOi4I" / Twitter
NEJM) Empagliflozina en pacientes con ICC y FEr. Estudio EMPEROR-Reduced – El rincón de Sísifo
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial | Nature Medicine
Thread by @hmkyale on Thread Reader App – Thread Reader App
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
CardsJC: EMPEROR-Preserved Trial - Cardionerds Twitter Journal Club
EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT
The All-Important Endpoint of a Medical Study
NEJM) Empagliflozina en pacientes con ICC y FE conservada. Estudio EMPEROR- Preserved – El rincón de Sísifo
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM
Estudio EMPEROR-Reduced, ¿fueron los resultados que esperábamos? Escuchemos a los expertos - SAC | Sociedad Argentina de Cardiología
